Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, affecting roughly 1 in 8,000 to 10,000 people worldwide. It causes progressive muscle weakness and a distinctive symptom called myotonia, where muscles contract normally but are slow to relax. Unlike many conditions people associate with “muscular dystrophy,” it reaches far beyond the muscles, affecting the heart, eyes, brain, and hormonal systems.
Two Types With Key Differences
There are two recognized forms. Type 1 (DM1) is caused by an abnormally long repeating stretch of DNA in a gene called DMPK. In healthy individuals, a specific three-letter sequence in this gene repeats 5 to 34 times. In people with DM1, that sequence repeats more than 50 times, and sometimes thousands of times. The longer the repeat, the more severe the disease tends to be.
Type 2 (DM2) involves a similar problem in a different gene, where a four-letter DNA sequence expands far beyond its normal length. DM2 is generally milder and lacks the severe congenital form that can appear in DM1. The two types also hit different muscle groups: DM1 primarily weakens muscles farther from the trunk (hands, forearms, lower legs, face), while DM2 tends to affect muscles closer to the trunk (hips, thighs, shoulders).
Both types are inherited in an autosomal dominant pattern, meaning a child needs only one copy of the expanded gene from one parent to develop the condition. A genetic screening study in New York State found that approximately 1 in 2,100 newborns carry the DM1 mutation, suggesting many cases go undiagnosed or are diagnosed late.
How the Genetic Mutation Causes Damage
The expanded DNA repeat doesn’t break the gene’s protein directly. Instead, it creates faulty RNA transcripts that get stuck inside cells. These defective RNA molecules trap proteins that normally regulate how cells build other proteins, particularly two called CUG-BP and muscleblind. When these regulators are hijacked, cells start producing embryonic versions of certain proteins instead of their adult forms. This widespread disruption of protein processing is why the disease affects so many different organ systems, not just muscle.
What Myotonia Feels Like
The hallmark symptom, myotonia, is an involuntary prolonged contraction of a muscle after you use it. You might grip a doorknob and find your hand won’t open smoothly, or clench your jaw and struggle to relax it. This stiffness is most noticeable after a period of rest. With repeated movement, the stiffness tends to ease, something known as the “warm-up phenomenon.” After a few contractions, the muscle loosens and moves more freely. Myotonia is more prominent in DM1 than DM2, and in infants with the congenital form it is typically absent altogether.
Symptoms Beyond Muscle Weakness
Myotonic dystrophy is often called a multisystem disease because its effects extend well beyond the muscles. People with DM1 frequently deal with a combination of problems that, on the surface, seem unrelated. This scattered presentation is one reason the condition is often misdiagnosed or diagnosed years after symptoms begin.
Heart
Cardiac problems are among the most serious complications. The electrical system of the heart is particularly vulnerable, and abnormal heart rhythms or conduction blocks (where electrical signals slow or fail to travel through the heart properly) show up on electrocardiograms in about 70% of patients. Most of these people don’t feel symptoms like dizziness or palpitations. Only about one in four patients with detectable heart rhythm problems actually notices anything wrong. The danger is that these conduction problems can progress silently and sometimes cause sudden cardiac death, estimated at roughly 1% of patients per year. Heart disease and pneumonia are the leading causes of death in both DM1 and DM2.
Eyes
Cataracts are a clinical hallmark. They often develop earlier in life than typical age-related cataracts and cause blurry or cloudy vision and glare around lights. An eye exam revealing early cataracts in a younger adult sometimes provides the first clue that leads to a myotonic dystrophy diagnosis.
Brain and Behavior
Brain involvement is highly variable. Many people experience excessive daytime sleepiness and fatigue that goes far beyond ordinary tiredness. Cognitive changes can include difficulty with planning, spatial reasoning, and executive function. A particularly characteristic feature is apathy, a reduced drive or initiative that is often accompanied by limited awareness of how the disease is affecting them. Mood disorders, anxiety, ADHD-like symptoms, and sleep disorders are also common. These neurological and behavioral features can significantly affect quality of life and relationships, sometimes more than the muscle weakness itself.
Endocrine System
Hormonal disruptions include an increased risk of diabetes, thyroid problems, high cholesterol, and reproductive hormone imbalances. Fertility can be affected in both men and women.
The Congenital Form
The most severe presentation is congenital myotonic dystrophy, which appears at birth and occurs only in DM1. Babies are born with profound low muscle tone, a weak cry, and difficulty feeding and breathing. About half of affected newborns develop significant respiratory problems, which are the leading cause of death in this group. The facial muscles are notably weak, giving infants a characteristic appearance with a tent-shaped mouth, drooping eyelids, and limited facial expression. Joint contractures, club feet, and skeletal abnormalities are common. Children who survive the neonatal period typically face intellectual disability and ongoing developmental challenges. This form is almost always inherited from the mother, and the repeat expansion tends to grow larger with each generation, a phenomenon called anticipation.
How It’s Diagnosed
Genetic testing is the gold standard and is both highly accurate and relatively straightforward. Clinical sensitivity and specificity are above 99%. For smaller repeat expansions, a standard DNA test using PCR can measure the number of repeats directly. For larger expansions, specialized techniques are used. One called triplet-repeat primed PCR can detect expansions of any size, though it doesn’t precisely measure very large ones. Historically, a technique called Southern blotting was the standard for detecting large expansions, but it has largely been replaced by faster methods in most diagnostic labs.
A doctor may suspect the diagnosis based on the combination of grip myotonia, characteristic facial weakness, early cataracts, and a family history of the condition. But because symptoms vary so widely, some people are diagnosed only after a relative receives a genetic diagnosis, prompting family screening.
Cardiac Monitoring
Because heart problems can develop silently and progress gradually, current guidelines recommend a baseline electrocardiogram and echocardiogram at diagnosis, followed by annual electrocardiograms for patients without symptoms. Echocardiograms (ultrasound imaging of the heart) are repeated every two to five years, and recent evidence suggests that for patients with no cardiac symptoms, pushing that interval closer to every five years is reasonable given the slow progression of heart changes. If conduction problems are found, closer monitoring or devices like pacemakers may be needed.
Anesthesia Risks
One of the most important practical things to know about myotonic dystrophy is that general anesthesia carries significant risks. Patients are unusually sensitive to sedatives, muscle relaxants, and inhaled anesthetics. In one review of 320 patients, about 15% experienced worsening muscle symptoms after general anesthesia, and a small number had permanent deterioration. Pulmonary complications dominate: in a study of 219 surgical patients, 89% of all complications involved the lungs.
Cold temperatures can trigger or worsen myotonia during surgery, so warming measures are critical. Certain drugs commonly used in anesthesia need to be avoided entirely. Regional anesthesia (numbing a specific area rather than putting the patient fully under) appears to carry fewer risks. Anyone with myotonic dystrophy should make sure their surgical and anesthesia team is aware of the diagnosis well before any procedure, even for routine operations.
Treatment and Life Expectancy
There is no cure for myotonic dystrophy, and no treatment currently slows the underlying disease process. Management focuses on addressing individual symptoms: medications to reduce myotonia, cardiac devices for dangerous heart rhythms, cataract surgery when needed, assistive devices for mobility, and support for cognitive and behavioral symptoms. Physical therapy and occupational therapy play important roles in maintaining function.
Gene-targeted therapies are in development. One approach uses synthetic molecules designed to bind the toxic RNA that drives the disease. A completed early-stage trial of one such therapy, baliforsen, showed it was well tolerated but did not reach high enough concentrations in muscle tissue to meaningfully reduce the disease target. Researchers concluded the approach has potential but needs better delivery methods to get enough drug into muscle cells.
Life expectancy depends heavily on the type and severity. DM1, particularly with earlier onset, significantly shortens lifespan, with respiratory failure and cardiac events as the primary causes of death. DM2 is milder but still reduces life expectancy. A Dutch study found that patients with DM2 died at a median age of about 71, compared to roughly 78 to 82 in matched comparison groups. The leading causes of death in DM2 were cardiac disease (31%), pneumonia (27%), and cancer (27%).